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INTRODUCTION
During the postpartum period, the majority of
women (92-98%) do not want to get pregnant in
2 months after delivery, based on current world
demographics and health surveys. During the post-
partum period, 66.5% wants to use contraception
in the first year, yet 40% of them does not get
contraception care due to many reasons.1-3 Post-
partum contraception is the righ test period to
start contraception use.2,3
Lactational Amenorrhea Method (LAM) as a
postpartum contraception, has resulted 98% in
effectiveness if the woman has not have
menstruation, exclusive breastfeeding, and the
infant age is less than 6 months.2-5 If LAM
requirements are not fulfilled, other effective
contraceptive methods are needed.4
Progestin hormonal contraception method can
be used as a postpartum contraception. However,
progestin is a short-term contraception. Implant is
a long-term contraception, which is effective for
3-5 years.2,6
Abstract
Objective: To evaluate the acceptability, effectivity and side
effects of Postplacental IUCD after vaginal delivery at Dr. Cipto
Mangunkusumo Hospital (RSCM) after 6 month of insertion.
Methods: A prospective study was conducted at RSCM Jakarta
during the period of August to October 2012. Postplacental IUCD
was inserted into the subjects’ uterus until it reached the fundus.
Follow up was done at 40-42 days and 6 months after delivery.
Results: A total of 234 women were recruited in this study, with
19.2% loss of follow up. No significant difference on subjects’
characteristics who came and loss of follow up in this study.
Expulsion was experienced by 5.1% subjects (total expulsion
4.1% and partial 1%) at the first visit on 40-42 days and 7.5%
subjects (total expulsion 0.6% and partial 6.9%) at the second
visit, after 6 months. 9.3% subjects had the IUCD removed at the
first and second visit. Among all of the subjects who had the IUCD
removed by request or had the expulsion, 61% were willing to do
reinsertion. The effectivity of IUCD was 100%, with 68.9%
subjects was still breastfeeding. The side effects were vaginal
discharge (23%), dysmenorrhea (4-21%), and spotting (2-10%).
Conclusion: The acceptability and effectivity of postplacental
IUCD after 6 months were 86.8% and 100%. Cummulative
expulsion rate were 12.6%, and the most common side effects
were vaginal discharge, dysmenorea, and spotting.
[Indones J Obstet Gynecol 2017; 5-4: 213-218]
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Abstrak
Tujuan: Mengevaluasi penerimaan, efektivitas dan efek samping
AKDR pascaplasenta pada persalinan pervaginam di RSCMselama periode 6 bulan setelah pemakaian.
Metode: Penelitian observasional kohort prospektif dilakukan diRSCM Jakarta pada Agustus-Oktober 2012. Alat kontrasepsi dalam
rahim (AKDR) pascaplasenta dipasang pada uterus hingga mencapai
fundus uteri. Penilaian dilakukan pada kunjungan 40-42 hari pasca-salin dan 6 bulan kemudian.
Hasil: Jumlah total subjek 234 orang, dengan 19,2% loss of follow
up. Tidak terdapat perbedaan bermakna antara subjek yang datang
dan loss of follow up. Ekspulsi terjadi pada 5,1% subjek (ekspulsitotal 4,1% dan parsial 1%) pada 40-42 hari pascasalin dan 7,5%
subjek (ekspulsi total 0,6% and parsial 6,9%) setelah 6 bulan
pemasangan. Total 9,3% subjek melepas AKDR pada kunjunganpertama dan kedua. Dari seluruh subjek yang melepas AKDR atas
permintaan atau mengalami ekspulsi, 61% di antaranya bersediadipasang ulang. Efektivitas AKDR 100%, dengan 68,9% subjek
masih menyusui. Efek samping antara lain keputihan (23%),
dismenorea (4-21%), dan perdarahan bercak (2-10%).
Kesimpulan: Penerimaan dan efektivitas AKDR pascaplasenta setelah
6 bulan pemakaian adalah 86,8% dan 100%. Ekspulsi kumulatifsebesar 12,6%, dan efek samping tersering adalah keputihan,
dismenorea dan perdarahan bercak.
[Maj Obstet Ginekol Indones 2017; 5-4: 213-218]
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IUCD can be applied during the postpartum
period, including post-placenta (in 10 minutes
after placenta delivery)3,5,7-13, immediate/delayed
(in 48 hours until before 6 weeks postpartum)14
and IUCD after puerperium or interval.11-12,15,16
The use of post-placental IUCD is relatively more
comfortable, safe, efficient with lower infection
incidence17,18, bleeding problem, perforation15, and
expulsion9,10,17,19 than immediate or delayed post-
partum insertion.16
Post-placenta IUCD has been introduced since
40 years ago in Indonesia.20 The acceptability of
post-placental IUCD Multiload Copper 250 (ML-
Cu250), for 3 months of observation, reaches
91.1%.21 The effectiveness of post-placental IUCD
reaches 2.4% delivery in 1 year.10 Factors affecting
acceptability are expulsion rate and side effects
such as bleeding and pain.8,11,12 The average of
post-placental IUCD expulsion rate ranges
cumulatively from 11% through 15% in many
countries. In Indonesia, post-placental IUCD
expulsion rate is estimated ranging from 6%
through 10%.14 Expulsion rate can be reduced by
post-placental insertion, done by experienced
installer, and placed precisely in fundus uteri.22
A previous study in RSCM had been done by
Badan Kependudukan dan Keluarga Berencana
Nasional (BKKBN). The research interviewed
subjects who were inserted IUCD 6 months after
delivery. The acceptability was 68% and 26% of
the subject removed the IUCD outside RSCM. The
most common side effects were lower abdominal
pain (40%), and the total expulsion rate was 6
percent.23
A study about the acceptability, effectiveness,
and side effects of post-placental IUCD Cu T380A
at RSCM with direct clinical evaluation is an
operational study which can be used to support
optimal postpartum care in Indonesia generally
and to support contraception care in RSCM.
Therefore, studies which can show these data are
required to be conducted.
METHODS
A prospective study was conducted in the
Obstetrics and Gynecology Department, FMUI-
RSCM Jakarta during the period of August to
October 2012. Patients who met the study criteria
were included in the study after signing informed
consent. The study protocol had been approved by
the RSCM ethics commission. Inclusion criteria:
subjects who were at term pregnancy and
scheduled to do vaginal delivery in RSCM, both
referral and patient from policlinic and ward.
Subject and partner were willing to participate in
the study and chose IUCD as post-placenta
contraception method.
Exclusion criteria included presence of uterus
anatomic abnormalities, history of menometrorrha-
gia or dysmenorrhea, history of blood clotting
disorders, history of fever or other clinical signs
and symptoms that were related to intrauterine or
intrapartum infection, history of previous ectopic
pregnancy, rupture of the fetal membrane more
than 24 hours before hospital admission, delivery
which occurred for 24 hours without significant
progress and postpartum bleeding.
Subjects who were included in the study would
be inserted with IUCD Cu T380A, immediately 10
minutes after placenta were delivered. IUCD was
inserted in uterine cavity until it reached fundus
with the help of the provider’s hand. Providers
were Obstetrics and Gynecology FMUI-RSCM
residents who were well-trained to do post-
placenta IUCD insertion. After insertion, subjects
were informed to come in 40-42 days postpartum
and 6 months postpartum. Subjects were given a
special card to assess bleeding, and to write down
address and contact number.
On the next visit, every subject was asked
whether there was IUCD which spontaneously
expelled, whether she still breastfed, and whether
she had gotten her menstrual period. If the patient
had got menstruation, patient was asked whether
there was any complaint, bleeding, and pain.
Patient was also asked whether there was a
pregnancy and other complaints were noted.
Subject was also asked about satisfaction in using
IUCD for 6 months.
Examination using speculum was performed on
each subject to assess detached thread from ostium
and any other pathology feature in the examination.
If IUCD threads were not seen in ostium, the doctor
would perform transvaginal USG to ensure the
existence of IUCD.
RESULTS
The total number of subjects participating in this
study was 234. All subjects were inserted with
post-placental IUCD Cu T380A after vaginal
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delivery both spontaneously and equipped in
RSCM. All subjects were asked and reminded by
phone to come in the first re-visit, which was 40-42
days postpartum and 6 weeks postpartum. Sub-
jects who did not come in the first re-visit were
re-contacted to come to second re-visit. However,
30 subjects did not come to first and second re-
visit, 15 subjects did not come to second re-visit,
19.2% subjects were loss of follow up. There
was no statistically significant difference in the
characte-ristics of the subject who came and were
loss of follow up.
Expulsions occured in 5.1% subjects (total
expulsion rate was 4.1% and partial expulsion rate
was 1%) in the 40-42 day visit and 7.5% subjects
(total expulsion rate was 0.6% and partial
expulsion rate was 6.9%) after 6 months. During
the first and second re-visit, 9.3% patients
removed IUCD, 2% subjects requested to remove
IUCD because they complained pain during sexual
intercourse, leukorrhea, and bleeding.
In patients who removed their IUCD outside
RSCM, the most common reasons were presence of
the thread which was palpable in the genitalia and
vaginal bleeding. IUCD thread could not be seen in
32.6% subjects in the first re-visit and 25%
subjects in the second re-visit. Of all the subjects
who were both expulsion and removed by request,
8.5% was re-explained and agreed to re-install the
IUCD.
There was no pregnancy in any subject for 6
months use of IUCD, 68.9% subjects still breastfed
yet 20.1% subjects had not got menstruation. The
most common side effects were leukorrhea (23%),
menstrual pain (4-21%), and spotting (2-10%).
Most of the subjects (45.3-60.1%) had no
complaint. Although some patients developed side
effects, the majority of the patients were satisfied
using post-placenta IUCD Cu T380A. Most of the
patients who removed IUCD outside RSCM were
not satisfied using IUCD.
Table 1. Subjects’ Characteristic based on Postplacental IUCD Acceptability
Characteristic Collectable subjects
(n=189)
Loss of follow up
(n=45)
p
Age
Mean (IK 95%) 27.21 (26.36-28.06) 27.11 (25.25-28.97) 0.938a
Median (IQR) 27.00 (22.00-31.00) 27.00 (23.00-31.50)
Age group
18 years, n (%) 11 (5.8) 3 (6.7)
19-25 years, n (%) 67 (35.4) 16 (35.6)
26-30 years, n (%) 56 (29.6) 14 (31.1) 0.982b
31-35 years, n (%) 32 (16.9) 6 (13.3)
>35 years, n (%) 23 (12.2) 6 (13.3)
Education
Non educated, n (%) 1 (0.5) 1 (2.2)
Elementary school, n (%) 12 (6.3) 4 (8.9) 0.982c
Junior high school, n (%) 48 (25.4) 13 (28.9)
Senior high school, n (%) 128 (67.7) 27 (60.0)
Obstetrical status
Primipara, n (%) 97 (51.3) 24 (53.3)
Multipara, n (%) 88 (46.6) 21 (46.7) 1.000c
Grande Multipara, n (%) 4 (2.1) 0 (0.0)
Note:aMann-Whitney statistical analysisbChi-square statistical analysiscKolmogorov-Smirnov statistical analysis
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Table 2. Six Months Lifetime Table
Variable N %
Pregnancy 0 0
Partial expulsion 14 7.9
Total expulsion 9 4.7
Acceptability 164 86.8
Loss of follow up 45 19.2
Total subjects recruited 234 -
Subjects included in this study 189 -
DISCUSSION
As a contraceptive method used during the
postpartum period, IUCD has many advantages.
Besides, it does not affect breast milk, IUCD is
a reversible contraception method and does not
need subject compliance to come in the certain
time, not depending on the time having sexual
intercourse and minimal pain when it  was
inserted post- partum. Ideal insertion time is 10
minutes after placenta is delivered or in 48 hours
after delivery, with higher expulsion rate in the
insertion after 48 hours.24
This study was an operational study which
studied about post-placenta IUCD Cu T380A which
was performed in RSCM. Evaluation was done in
40-42 days and 6 months after insertion. Previous
study about post-placenta IUCD, performed follow
up in post-puerperial period (40-42 days), 6
months, and 1 year after delivery.8-12,24,25
The acceptability of post-placenta IUCD Cu T
380A until the end of the study was 86.9%.
Acceptability of post-placental IUCD in the
previous study using IUCD ML Cu 250 was
91.1%21, while in the study which was conducted
in Turkey compared post-placental insertion,
delayed and interval, acceptability of post-placenta
IUCD reached. 72.0%26 Lower acceptability
compared with previous study which was done
follow up for 3 months postpartum was affected
by low subject compliance, lack of information
which was given in patient education. 7.4%
subjects removed IUCD outside RSCM, majority of
which due to detached thread complaint (3.2%).
Effectiveness of IUCD for 6 months in this study
was 100%. All subjects who used IUCD until the
end of the study, there was no one getting
pregnant. That number was also affected by breast-
feeding activity until 6 months postpartum in
68.9% subjects. Effectiveness of the MAL was
98%.2-5 Failure rate or pregnancy incidence was
less than 1% in the first year use of IUCD. In the
long-term study sponsored by WHO, average of the
failure rate per year was 0.4% or lower, and
cumulative failure rate in 12 years was 2.2%,
which was comparable to tube sterilization.19 In
the previous studies, effectiveness after one year
use of IUCD was assessed. Further study to assess
long-term effectiveness of post-placental IUCD
needs to be done.8-12,17,24
Expulsion assessment in this study was obtained
197 from the first re-visit (40-42 days post-
partum), 90.4% of subjects IUCD was located fully
inside uterine cavity, most of IUCD shifted to cervix
in 1% and 4.1% of cases encountered total
expulsion. In visit of 6 months IUCD use, 0.6% of
cases encountered total expulsion and 6.9% of
cases encountered partial expulsion, so that
cumulative expulsion rate was 12.6%. Based on the
previous study, cumulative expulsion rate after 6
months insertion was, in China 13.3%12, in Mali
15%9, and in Turkey 33.4%.10
A study conducted in India and Turkey had
lower cumulative expulsion rate which were
10.68%24 and 7%.8 The most common factors
affecting expulsion risks included the experience
and expertise of health care provider who
performed insertion and insertion technique.10 In
this study, all installers were trained before the
study was conducted so that installer ability was
considered the same, yet installer experience
became factor that needed to consider.
Evaluation of IUCD distance from fundus uteri
could be assessed by trans-vaginal USG to
determine expulsion objectively. In the study
conducted in Brazil, trans-vaginal USG was
performed to assess IUCD position in its exact place
if IUCD distance was not more than 3 mm from
fundus.27 In the next study, it could be evaluated
further about exact distance IUCD, by trans-vaginal
USG evaluation in each re-visit.
In this study, there was no perforation, one IUCD
malposition was occured in subjects with
dyspareunia and reinserted after that IUCD was
removed. Numerous multicenter studies found no
perforation or infection in post-placental IUCD
user.24 In patients whose intrauterine IUCDs were
not detected on USG, and from anamnesis the
patient did not feel any detached IUCD from
genitalia, perforation should be removed by
Indones J
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abdominal x ray examination, which was seldomly
performed in this study.24
Infection in puerperal period did not happen in
this study. Welkovic et al, stated that 3.4% of IUCD
users complained puerperal infection but it was
not statistically significant different with subjects
not using IUCD.28 Non-itchy and non-stinky
leukorrhea as unexpected complaints by the
authors was 23.1%. 90% of which still satisfied
using IUCD although the complaints existed.
Leukorrhea were not found in IUCD Cu T380A
users.25 Eroglu et al stated that leukorrhea
complaints which were confirmed by the
existence of pathogen were only 1.6% in 6 months
postpartum and there was no infection in 8 weeks
postpartum in postpartum IUCD insertion.15 The
weakness of this study was no analysis for
leukorrhea as complaint, therefore further studies
to analyze leukorrhea complaint objectively by
finding the pathogens in subject with leukorrhea
complaints are needed to be done.
Welkovic found menorrhagia in IUCD users.28 In
this study, subjective menorrhagia complaint was
5% and objectively was 2.8% that in the subject’s
note, bleeding was no more than 5 times changing
bandages per day. Thirty three percent of subjects
with menorrhagia did not satisfy because of the
bleeding. They requested to remove IUCD.
Welkovic et al, stated that bleeding and infection
after postpartum IUCD insertion were not
associated with a lot of bleeding incidence in
menstrual cycle.28
In the cumulative side effect assessments,
bleeding other than menstruation was spotting
subjectively in 15.3% of the subjects and
objectively in 4.8% of the subjects. It was because
subject did not note properly in the same day.
However, 75% of the subjects satisfied using IUCD
although there were spotting complaints. All inert
IUCD and copper release increased bleeding
volume in menstruation when using IUCD, the
most possible causes were increase of fibrinolysis
activity and local effect on prostacyclin/
thromboxane balance in endometrium. New
generation IUCD such as Cu T380 and Multiload
were reported to cause 50-75% increase in
menstrual blood volume.29
CONCLUSION
The acceptability and effectiveness for 6 months
were 86.8% and 100%. Expulsion rate side effect
for 6 months was cumulatively 12.6%. Other side
effects were leukorrhea, menstrual pain, and
spotting.
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